Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | KCNN4 | O15554 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6270358 | 0.89 | MAPK1 (0.44) | MAPK1CES1KCNN4ALDH1A1ALOX15 | |
| SCHEMBL7056377 | 0.85 | MAPK1 (0.41) | MAPK1CES1KCNN4ALDH1A1ALOX15 | |
| SCHEMBL11302190 | 0.81 | ALDH1A1 (0.50) | MAPK1CES1KCNN4ALDH1A1ALOX15 | |
| SCHEMBL28528178 | 0.81 | KCNN4 (0.39) | MAPK1CES1KCNN4ALDH1A1ALOX15 | |
| SCHEMBL8032767 | 0.81 | CES1 (0.41) | MAPK1CES1KCNN4ALDH1A1ALOX15 | |
| SCHEMBL11781678 | 0.81 | CA4 (0.42) | MAPK1CES1KCNN4ALDH1A1ALOX15 | |
| SCHEMBL9576889 | 0.81 | KCNN4 (0.35) | MAPK1CES1KCNN4ALDH1A1ALOX15 | |
| SCHEMBL30655989 | 0.79 | PTPN1 (0.47) | MAPK1ALDH1A1CYP2B6CYP3A4 | |
| SCHEMBL628803 | 0.79 | CES1 (0.40) | MAPK1CES1KCNN4ALDH1A1ALOX15 | |
| SCHEMBL2341249 | 0.79 | CES1 (0.48) | MAPK1CES1KCNN4ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 987 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119613414-A | Non-azolanet Process for the preparation of tam | 上海皓元医药股份有限公司 | 2025-03-14 | — | — | CN | claimed |
| EP-3925948-B1 | INTERMEDIATE OF ERIBULIN, SYNTHESIS METHOD THEREFOR AND USE THEREOF | BEIJING TIENYI LUFU PHARMATECH CO LTD (CN) | 2024-08-07 | — | — | EP | claimed |
| US-20240051920-A1 | AN IMPROVED HIGHLY EFFICIENT PROCESS FOR THE PREPARATION OF NINTEDANIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | BDR LIFESCIENCES PRIVATE LIMITED (IN) | 2024-02-15 | — | — | US | claimed |
| CN-117486966-A | Method for synthesizing brassinolide | 山东成武泽大泛科化工有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-117219855-A | Sodium ion battery electrolyte and sodium ion battery | 山东立中新能源材料有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-111465594-B | Synthesis of 2-indolinones known as intermediates for the preparation of Nidamibu | 费米有限公司 | 2023-11-07 | — | — | CN | claimed |
| EP-3276696-B1 | FUNCTIONAL LAYER FORMING COMPOSITION AND METHOD FOR MANUFACTURING THE SAME | SEIKO EPSON CORP (JP) | 2023-10-11 | — | — | EP | claimed |
| CN-111662223-B | Indolinone derivatives and process for preparing intermediates thereof | 四川科伦药物研究院有限公司 | 2023-07-14 | — | — | CN | claimed |
| CN-111848369-B | Eribulin intermediate and synthesis method and application thereof | 北京天一绿甫医药科技有限公司 | 2023-06-30 | — | — | CN | claimed |
| WO-2023103137-A1 | ORTHOESTER MIXTURE PHARMACEUTICAL EXCIPIENT, PREPARATION METHOD, AND TOPICAL SUSTAINED-RELEASE DRUG DELIVERY PREPARATION CONTAINING EXCIPIENT | 安徽大学 | 2023-06-15 | — | — | WO | claimed |
| US-5807912-A | PURIFICATION; HEATING | GENERAL ELECTRIC COMPANY (US) | 1998-09-15 | — | — | US | claimed |
| EP-0834525-A2 | Ortho esters as bisphenol A scavenger in polycarbonate product | GENERAL ELECTRIC COMPANY (US) | 1998-04-08 | — | — | EP | claimed |
| EP-0606710-B1 | Photochemical generation of dyes | MINNESOTA MINING & MFG (US) | 1997-10-08 | — | — | EP | claimed |
| US-5389498-A | Photosensitive element for production of near infrared absorbing images; magnetic recording media | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-02-14 | — | — | US | claimed |
| EP-0606710-A2 | Photochemical generation of dyes | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-07-20 | — | — | EP | claimed |
| EP-0315464-B1 | STABILIZED ISOTHIAZOLONE COMPOSITIONS | ROHM AND HAAS COMPANY (US) | 1993-01-27 | — | — | EP | claimed |
| US-4906274-A | Organic stabilizers | ROHM AND HAAS COMPANY (US) | 1990-03-06 | — | — | US | claimed |
| EP-0315464-A1 | Stabilized isothiazolone compositions | ROHM AND HAAS COMPANY (US) | 1989-05-10 | — | — | EP | claimed |
| CN-86100772-A | 2,3-dimethoxy-5-methyl isophthalic acid, 4-benzoquinones synthetic method | — | 1987-01-31 | — | — | CN | claimed |
| US-4252738-A | 1,2-Halohydrincarboxylic acid esters and a process for their preparation | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051920-A1 | AN IMPROVED HIGHLY EFFICIENT PROCESS FOR THE PREPARATION OF NINTEDANIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | JAK1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, INMT | MAPK1 847/4885CES1 3411/4885KCNN4 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.